Last reviewed · How we verify
Propofol infusion
Propofol infusion, marketed by Pusan National University Hospital, is a well-established anesthetic agent in the healthcare sector. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. However, the lack of reported revenue and key trial results poses a primary risk in assessing its competitive landscape and future market performance.
At a glance
| Generic name | Propofol infusion |
|---|---|
| Also known as | Target-controlled infusion (TCI) of propofol, propofol 2%, Diprivan, Fresofol |
| Sponsor | Pusan National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Total Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy (PHASE4)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- Target-controlled Infusion With Propofol in the Emergency Department : a Prospective Study on 45 Adult Patients (PHASE4)
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) (PHASE3)
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propofol infusion CI brief — competitive landscape report
- Propofol infusion updates RSS · CI watch RSS
- Pusan National University Hospital portfolio CI